Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans

Psychopharmacology

Volumn 157, Issue 2, 2001, Pages 151-162

  Walsh, S L ^a   Strain, E C ^a   Abreu, M E ^a   Bigelow, G E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Butorphanol; CI 977; Enadoline; Human; Hydromorphone; Kappa opioid; Mixed agonist antagonist; Mu opioid

Indexed keywords

BUTORPHANOL; ENADOLINE; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; PLACEBO; PSYCHEDELIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPERSONALIZATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EUPHORIA; FEMALE; HUMAN; MALE; MIOSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; SEDATION; SUBSTANCE ABUSE; URINE VOLUME; VERTIGO; VISUAL DISORDER;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; BENZOFURANS; BUTORPHANOL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEROIN DEPENDENCE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA;

EID: 0034873586     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130100788     Document Type: Article

References (56)

1. Lysergic acid diethlyamide (LSD-25): I. Physiological and perceptual responses
2. Effects of receptor-selective opioids on operant behavior in morphine-treated and untreated rats
3. Systemic and regional hemodynamic and biological effects of a new κ-opioid agonist, niravoline, in healthy volunteers
4. 3H]-CI-977: A highly selective ligand for the k-opioid receptor in both guinea-pig and rat forebrain
5. Chronic 1-alpha-acetylmethadol (LAAM) in rhesus monkeys: Tolerance and cross-tolerance to the antinociceptive, ventilatory, and rate-decreasing effects of opioids
6. Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys
7. The antinociceptive activity of kappa- but not delta-opioid receptor agonists is maintained in morphine-tolerant neuropathic rats
8. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study
9. PD117302: A selective agonist for the kappa-opioid receptor
10. Selectivity of ligands for opioid receptors
11. Differential cross-tolerance to opioids in squirrel monkeys responding under a shock titration schedule
12. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output
13. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment
14. Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys
15. Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey
16. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects
17. Discriminative stimulus and subjective effects of opioids with mu and kappa activity: Data from laboratory animals and human subjects
18. Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs, (B) A short-term "direct" addiction test
19. Reversal by k-agonists of peritoneal irritation-induced ileus and visceral pain in rats
20. Kappa receptor medicated opioid dependence in rhesus monkeys
21. Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration
22. Butorphanol: A review of its pharmacological properties and therapeutic efficacy
23. Comparative pharmacological and biochemical studies between butorphanol and morphine
24. CI-977, a novel and selective agonist for the kappa-opioid receptor
25. Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication
26. Assessment of abuse potentiality of morphine-like drugs (methods used in man)
27. Progress report on studies from the Clinical Pharmacology Section of the Addiction Research Center
28. Progress report on studies from the Clinical Pharmacology Section of the Addiction Research Center
29. Respiratory effects of butorphanol and pethidine
30. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo
31. The reinforcing and subjective effects of morphine in post-addicts: A dose-response study
32. Evidence that nalorphine, butorphanol, and oxilorphan are partial agonists at a kappa-opioid receptor
33. Respiratory effects of opioid full and partial agonists in rhesus monkeys
34. Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2′-hydroxy-5,9-dimethyl-6,7 benzmorphan (cyclazocine, WIN-20,740, ARC II-C-3)
35. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man
36. Analysis of the antinociceptive actions of k-opioid agonist enadoline (CI-977) in neonatal and adult rats: Comparison to k-opioid receptor mRNA ontogeny
37. Interactions between kappa opioid agonists and cocaine - Preclinical studies. New medications for drug abuse
38. Analgesic efficacy of the k-receptor agonist, enadoline, in dental surgery pain
39. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain
40. Psychotomimesis mediated by κ opiate receptors
41. Discriminative stimulus effects of butorphanol: Influence of training dose on the substitution patterns produced by mu, kappa and delta opioid agonists
42. The pharmacology of butorphanol, a 3,14-dihydroxy-morphinan narcotic antagonist analgesic
43. Differential antagonism of hydromorphone and pentazocine effects in human volunteers
44. Drug discrimination assessment of agonist-antagonist opioids in humans: A three-choice saline-hydromorphone-butorphanol procedure
45. Drug discrimination in human postaddicts: Agonist-antagonist opioids
46. Discriminative stimulus properties of naloxone, butorphanol, nalbuphine and hydromorphone in opioid-dependent humans
47. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans
48. Opioid analgesics and antagonists
49. Kappa opioids: Therapeutic considerations in epilepsy and CNS injury
50. EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302
51. κ-opioid receptor effects of butorphanol in rhesus monkeys
52. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans
53. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids
54. A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers
55. Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers